We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
Molecular interactions form the mechanistic foundation of virtually all biological processes, from signal transduction and immune recognition to enzymatic catalysis and gene regulation. Quantitative characterization of these interactions—determining how strongly molecules bind, how rapidly complexes form and dissociate, and the thermodynamic forces driving association—is indispensable for drug discovery, therapeutic optimization, and mechanistic understanding of disease pathways. Profacgen offers a comprehensive Molecular Interaction & Binding Assays platform integrating multiple biophysical detection technologies to deliver precise interaction parameters across diverse molecular classes, sample formats, and project phases. Our integrated approach combines surface-based, solution-phase, and cell-based methodologies to provide complementary insights that advance programs from early target validation through regulatory-compliant therapeutic characterization.
Introduction to Molecular Interaction Analysis
Binding interactions between biological macromolecules are governed by the interplay of enthalpic contributions (hydrogen bonding, van der Waals contacts, electrostatic interactions) and entropic contributions (hydrophobic effect, conformational freedom, solvent reorganization). The quantitative description of these interactions requires measurement of multiple parameters:
Affinity (KD or KA): The equilibrium dissociation constant describing the ratio of bound to free species at thermodynamic equilibrium; inversely related to binding strength
Kinetics (kon, koff): The association and dissociation rate constants that determine how rapidly complexes form and persist; residence time (τ = 1/koff) increasingly recognized as an independent therapeutic optimization parameter
Thermodynamics (ΔH, ΔS, ΔG): The enthalpy, entropy, and free energy changes accompanying complex formation, revealing the molecular forces driving recognition and guiding structure-based design
Stoichiometry (n): The molar ratio of binding partners in the complex, indicating oligomeric state, valency, and potential cooperativity
No single technique captures all parameters with optimal precision. Surface plasmon resonance (SPR) excels at kinetic resolution; isothermal titration calorimetry (ITC) provides complete thermodynamic decomposition; bio-layer interferometry (BLI) enables high-throughput screening; and resonance energy transfer methods (FRET/BRET) preserve native cellular context. Profacgen's multi-platform integration ensures that each project employs the most appropriate technology or combination of technologies to answer the specific scientific question at hand.
Our Binding Assay Technologies
Surface Plasmon Resonance (SPR)
SPR is the gold-standard label-free technology for real-time kinetic analysis of molecular interactions. Changes in refractive index at a gold sensor surface upon binding are measured as resonance unit (RU) shifts, enabling determination of kon, koff, and KD without molecular modification.
Instrumentation: Biacore 8K, T200 systems with parallel injection capacity and automated sample handling
Kinetic Range: kon: 103–107 M−1s−1; koff: 10−6–10−1 s−1; KD: mM to pM
BLI measures wavelength shifts of reflected light from disposable biosensor tips upon molecular binding. The dip-and-read format enables rapid, crude-sample-compatible analysis without microfluidic infrastructure.
Instrumentation: Octet RED96e with automated plate handling and on-board regeneration
MST quantifies affinity by measuring the thermophoretic movement of fluorescent molecules in a microscopic temperature gradient. Changes in hydration shell, charge, and size upon complex formation alter thermophoretic mobility.
Instrumentation: Monolith NT.115 with standard and premium capillary formats
Affinity Range: KD: mM to nM; solution-phase measurement without immobilization
Key Applications: Membrane protein interactions, fragment screening in complex matrices, protein-small molecule binding, intracellular target engagement
ITC measures heat exchange upon sequential titration of a ligand into a macromolecule, providing direct determination of KD, stoichiometry (n), enthalpy change (ΔH), and entropy change (ΔS) from a single experiment.
Instrumentation: MicroCal iTC200 with 200 µL cell volume and 0.2 µcal detection sensitivity
Affinity Range: KD: µM to nM; sample requirement as low as 20 µM × 200 µL
Fluorescence resonance energy transfer (FRET) and bioluminescence resonance energy transfer (BRET) detect molecular proximity through non-radiative energy transfer between donor and acceptor chromophores, enabling live-cell interaction mapping.
Equilibrium affinity describes the strength of binding at thermodynamic steady state. Profacgen determines affinity across multiple platforms to ensure platform-independent confirmation:
Direct KD Determination: Saturation binding curves from SPR, BLI, or radioligand assays yielding KD from tracer concentration at half-maximal binding
Competition-Derived Ki: IC50 values corrected by Cheng-Prusoff transformation to yield tracer-independent affinity estimates
Solution-Phase KD: ITC and MST providing affinity in free solution without surface immobilization artifacts
Kinetics
Kinetic rate constants reveal the temporal dynamics of complex formation and dissociation, enabling residence time optimization as an independent drug design parameter:
Association Kinetics (kon): Diffusion-limited encounter rates typically 105–106 M−1s−1 for protein-protein interactions; electrostatic steering can accelerate to 108–109 M−1s−1 for charged partners
Dissociation Kinetics (koff): Ranges from microseconds (weak, transient interactions) to days (high-affinity therapeutic antibodies); residence time τ = 1/koff directly correlates with pharmacodynamic duration
Kinetic Mechanism Classification: One-step binding, conformational selection (induced fit), and two-step binding with intermediate states distinguished by global kinetic fitting and thermodynamic correlation
Enthalpy-Driven Binding (ΔH < 0, –TΔS > 0): Favorable hydrogen bonding and electrostatic contacts dominate; typically exhibits high specificity and slow dissociation; optimized by directed hydrogen bond formation
Entropy-Driven Binding (ΔH > 0, –TΔS < 0): Hydrophobic effect and desolvation dominate; often associated with large nonpolar surface burial; optimized by increasing hydrophobic contact area
Enthalpy-Entropy Compensation: Common observation where affinity improvements from increased enthalpy are offset by entropic penalties; breakthrough optimization requires decoupling this compensation through conformational constraint or directed water displacement
Applications
Antibody Screening and Therapeutic Optimization
Comprehensive kinetic and thermodynamic profiling accelerates antibody discovery from hybridoma screening through clinical candidate selection:
Affinity Maturation Monitoring: Iterative BLI or SPR screening of phage display or yeast display libraries, tracking koff reduction as the primary optimization metric beyond KD.
Developability Assessment: Correlation of kinetic parameters with biophysical properties (aggregation, viscosity, thermal stability) to eliminate kinetically improved but manufacturably compromised variants.
Biosimilar Kinetic Fingerprinting: Head-to-head SPR or BLI comparison of biosimilar and innovator antibodies with statistical equivalence testing for regulatory submission.
Receptor-Ligand Studies
Quantitative characterization of GPCR, RTK, nuclear receptor, and ion channel interactions with native and therapeutic ligands:
Orthosteric and Allosteric Pharmacology: Kinetic discrimination of competitive, non-competitive, and allosteric modulation through tracer displacement patterns and dissociation rate perturbation.
Residence Time Optimization: Structure-kinetic relationship establishment for GPCR antagonists and kinase inhibitors, correlating koff with in vivo duration and selectivity.
Cellular Target Engagement: Live-cell bioluminescence resonance energy transfer assays and CETSA confirmation of intracellular receptor occupancy by membrane-permeable compounds.
Epitope Characterization
Systematic mapping of antibody binding sites to guide combination therapy, intellectual property strategy, and antibody engineering:
Epitope Binning: Competitive displacement profiling using SPR or BLI to classify antibodies into spatially distinct epitope clusters; pairwise competition matrices visualized for rapid pattern recognition.
Fine Epitope Mapping: Alanine scanning, peptide tiling, and domain deletion mutants combined with kinetic perturbation analysis to localize binding to specific residues or structural elements.
Cross-Reactivity Assessment: Kinetic comparison across species orthologs, isoforms, and paralogs to predict preclinical translation and diagnostic specificity.
Multi-Platform Technology Integration: SPR, BLI, MST, ITC, FRET, and BRET capabilities within a single service provider enable cross-validation, platform selection optimization, and comprehensive mechanistic insight from orthogonal measurements
Kinetic-First Optimization Philosophy: We prioritize residence time (τ = 1/koff) as an independent therapeutic parameter beyond equilibrium affinity, aligning with clinical evidence that sustained target engagement drives superior efficacy and durability
High-Throughput Screening Capacity: BLI single-cycle kinetics enabling 500+ antibody profiles per week; Biacore 8K parallel injection for 8-sample simultaneous analysis; automated data processing and LIMS integration
Solution-Phase Validation: ITC and MST providing affinity and thermodynamics in free solution without surface immobilization artifacts, essential for membrane proteins, aggregation-prone targets, and hydrophobic ligands
Live-Cell Interaction Capability: FRET and BRET platforms preserving native post-translational modifications, correct subcellular localization, and dynamic signaling context unavailable in purified systems
Regulatory-Compliant Operations: GLP-aligned assay validation, instrument qualification (IQ/OQ/PQ), software validation, and full audit trails supporting IND, BLA, and diagnostic submission
Representative Case Studies
Case 1: Multi-Platform Integration for a Difficult-to-Express Membrane Protein Target
Background:
A drug discovery program targeting a G protein-coupled receptor (GPCR) for metabolic disease encountered conflicting affinity data across platforms: SPR with detergent-solubilized receptor yielded KD = 50 nM, while radioligand filtration binding in lipid vesicles reported KD = 2 nM. The discrepancy threatened lead optimization direction, as medicinal chemistry relied on accurate affinity ranking for structure-activity relationship establishment.
Our Solution:
Profacgen implemented a multi-platform integration strategy: (1) SPR with three different detergent micelle conditions and nanodisc reconstitution to assess detergent artifact contribution; (2) MST in solution with fluorescently labeled ligand and receptor-containing lipid nanoparticles to eliminate surface immobilization entirely; (3) a live-cell bioluminescence resonance energy transfer assay using luminescent receptor fusion constructs and fluorescent ligands to capture native membrane context; and (4) ITC with purified receptor in optimized lipid bicelles for thermodynamic mechanism validation.
Final Results:
The integrated analysis revealed that the target GPCR adopted a detergent-dependent conformational equilibrium: the detergent-solubilized form favored an inactive state with 25-fold reduced ligand affinity, while nanodisc and live-cell formats preserved the native high-affinity state. MST in lipid nanoparticles (KD = 1.8 nM) and live-cell bioluminescence resonance energy transfer assays (KD = 2.3 nM) converged with radioligand data, establishing the true affinity. ITC further revealed that the affinity difference was enthalpic in origin (ΔΔH = –4.2 kcal/mol), consistent with detergent-disrupted hydrogen bonding networks. These insights redirected the screening cascade toward live-cell and nanodisc formats, rescuing multiple lead series that had been erroneously deprioritized based on SPR detergent artifacts.
Case 2: Thermodynamic-Guided Affinity Maturation of an Anti-TNF-α Nanobody
Background:
A biotechnology company developing a single-domain antibody against TNF-α for ophthalmic delivery required sub-picomolar affinity to achieve therapeutic duration in the vitreous humor, where rapid clearance limits conventional antibody residence. Standard affinity maturation by yeast display yielded variants with improved KD but progressively worsened solubility and formulation characteristics, suggesting that affinity gains came at the cost of unfavorable thermodynamic properties.
Our Solution:
Profacgen introduced thermodynamic filtering into the maturation cascade: (1) BLI primary screening of 1,200 variants for koff < 10−5 s−1; (2) ITC secondary screening of 48 hits to identify enthalpy-optimized binders (ΔH < –20 kcal/mol) with minimal entropic penalty; (3) correlation of thermodynamic parameters with biophysical properties (aggregation temperature, colloidal stability) to eliminate variants with favorable kinetics but poor developability; (4) structural modeling of selected variants to rationalize enthalpy-entropy balance and guide final library design.
Final Results:
A variant with KD = 0.08 pM, koff = 4 × 10−6 s−1 (τ = 69 hours), and favorable enthalpy-entropy balance (ΔH = –24.3 kcal/mol, –TΔS = –2.1 kcal/mol) was identified. Unlike earlier enthalpy-entropy compensated variants, this candidate maintained high solubility (>100 mg/mL) and low viscosity, enabling intravitreal formulation. The thermodynamic profile indicated that affinity was driven by extensive hydrogen bonding rather than hydrophobic collapse, explaining the improved colloidal properties. The nanobody entered IND-enabling studies with a differentiated profile: picomolar affinity, multi-day residence time, and manufacturable formulation properties.
Q: How do I select the appropriate binding assay technology for my project?
A: Technology selection depends on the molecular system, required parameters, sample format, and project phase. SPR is preferred for high-precision kinetics, bivalent analysis, and regulatory studies. BLI excels in high-throughput screening and crude sample analysis. MST is optimal for membrane proteins and solution-phase measurements without immobilization. ITC provides essential thermodynamic decomposition and stoichiometry. FRET/BRET preserves live-cell context for physiological relevance. For comprehensive characterization, we recommend a tiered approach: BLI for initial screening, SPR for lead validation, ITC for thermodynamic mechanism, and FRET/BRET for cellular confirmation. Profacgen provides consultation to design the optimal technology cascade for each project.
Q: What is the difference between affinity and kinetics, and why measure both?
A: Affinity (KD) is an equilibrium parameter describing binding strength at steady state, calculated as the ratio koff/kon. Kinetics describe the rates of complex formation (kon) and dissociation (koff). Two interactions with identical KD can have fundamentally different kinetic profiles: one with rapid on/off rates (transient binding) versus one with slow on/off rates (sustained binding). The latter typically provides prolonged pharmacodynamic effect, improved tumor penetration, and reduced dosing frequency. Measuring both enables rational optimization of residence time as an independent parameter beyond equilibrium affinity, and reveals mechanistic information about the binding pathway (conformational selection versus induced fit).
Q: Can membrane protein interactions be studied by SPR and BLI?
A: Yes, with appropriate reconstitution strategies. Detergent-solubilized membrane proteins can be captured via affinity tags or amine coupling, though detergent choice critically affects conformation and affinity. Alternative formats include: (1) lipid reconstitution in nanodiscs or liposomes for native membrane context; (2) proteoliposome capture on hydrophobic sensor surfaces; (3) cell membrane preparations with oriented receptor presentation; and (4) whole-cell SPR formats. For challenging membrane targets, Profacgen often recommends MST or live-cell resonance energy transfer assays as complementary or primary methods, as these avoid surface immobilization entirely and preserve the native lipid environment. We design platform selection based on target stability, ligand properties, and the specific scientific question.
Q: How does thermodynamic analysis guide drug design beyond affinity optimization?
A: Thermodynamic decomposition (ΔH, ΔS, ΔCp) reveals the molecular forces driving binding, enabling rational optimization that affinity alone cannot guide. Enthalpy-driven interactions (large negative ΔH) typically feature extensive hydrogen bonding and high specificity, correlating with slow dissociation and favorable selectivity profiles. Entropy-driven interactions (positive ΔS) often involve large hydrophobic surface burial, which can improve affinity but may compromise solubility and specificity. Medicinal chemists use thermodynamic data to: (1) prioritize enthalpic improvements through directed hydrogen bonding; (2) avoid excessive hydrophobicity that drives aggregation; (3) identify enthalpy-entropy compensation breakpoints where affinity improvements plateau; and (4) design ligands with optimal balance for formulation and in vivo performance. ITC is the only technique that experimentally determines both ΔH and KD, enabling this decomposition without empirical assumptions.
Q: What is the role of live-cell FRET/BRET in interaction analysis?
A: Live-cell FRET and BRET provide interaction data in the most physiologically relevant context: intact cells with native post-translational modifications, correct subcellular localization, and dynamic signaling environment. Unlike purified in vitro systems, live-cell methods capture: (1) compartment-specific interactions (nuclear versus cytoplasmic versus membrane); (2) signaling-dependent interaction dynamics (agonist-induced complex formation); (3) competition from endogenous binding partners; and (4) the effects of cellular redox state, pH, and metabolite concentration on binding. These methods are essential for validating that in vitro biophysical data translate to cellular physiology, and for identifying context-dependent interactions invisible to purified systems. Profacgen integrates live-cell data with SPR/ITC measurements to build mechanistic models spanning from molecular to cellular scales.
Q: What is the typical project timeline for molecular interaction characterization?
A: Standard timelines vary by technology and project scope: (1) 2–3 weeks for single-pair SPR or BLI kinetic characterization with available reagents; (2) 4–6 weeks for assay development including immobilization optimization and validation; (3) 6–8 weeks for high-throughput BLI screening of 100+ candidates; (4) 8–10 weeks for comprehensive multi-platform profiling (SPR + ITC + FRET/BRET) with thermodynamic and cellular validation; (5) 10–12 weeks for full GLP-compliant validation with instrument qualification and regulatory documentation. Biosimilar comparability studies typically require 6–8 weeks including statistical equivalence analysis. Epitope binning panels with 20+ antibodies require 4–6 weeks for matrix generation and clustering analysis.
References:
Tummino PJ, Copeland RA. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry. 2008;47(20):5481-5492.
Ladbury JE, Klebe G, Freire E. Adding calorimetric data to decision making in lead discovery: a hot tip. Nature Reviews Drug Discovery. 2010;9(1):23-27.
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
